ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Multicentric comparative study of botulinum toxin treatment in patients with hemifacial spasm.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHemifacial spasm (HFS) is a neurological disorder characterized by involuntary contractions of the facial muscles. Botulinum toxin (BTX-A) is an effective treatment, but its efficacy may vary across different geographical contexts. This multicentric study aims to compare the efficacy of BTX-A in treating HFS between centers in Morocco and France.
methodsA retrospective study was conducted with 128 patients diagnosed with HFS, distributed between one center in Morocco and two centers in France. Parameters studied included age, sex, average treatment duration, dose administered, injection sites, injection frequency, and adverse effects. The results were analyzed separately for primary and secondary HFS. An HSF-8 score was used to evaluate treatment outcomes, assessing patients before treatment and two months after receiving BTX-A injections.
resultsThis multicentric study assessed the efficacy of botulinum toxin (BTX-A) for treating hemifacial spasm (HFS) in centers in France and Morocco. Among the 128 patients included, 75% were women, with a mean age of 61.5 years. On average, patients had been receiving BTX-A injections for 6.49 ± 5.4 years, experiencing a mean self-reported improvement of 94.7% ± 2.3%. The treatment effect lasted approximately 3.15 ± 1.2 months per injection. Notable differences were observed between France and Morocco regarding the average dose per injection and injection frequency. Side effects were observed in 39.84% of patients in France compared to 10.94% in Morocco, but there was no significant difference. The most frequently reported side effects included ptosis, diplopia, and dry eyes. These effects are generally temporary and did not require discontinuation of treatment. The efficacy of BTX-A was objectively measured using the HFS-8 score, with significant improvements observed in both countries. Despite variations in therapeutic approaches, the overall efficacy of BTX-A remained comparable between the two countries, indicating consistent therapeutic outcomes across geographical contexts.
conclusionThis multicentric study confirms the efficacy of botulinum toxin (BTX-A) in the treatment of HFS, with significant improvements and a well-tolerated side effect profile. While differences exist in treatment practices between Morocco and France, the overall efficacy of the treatment remains comparable, underscoring the reliability of BTX-A as an effective therapy across different geographical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.